Lotyšsko -
lotyština -
Zāļu valsts aģentūra
recreol 50 mg/g ziede
grindeks, as, latvia - dekspantenols - ziede - 50 mg/g
Lotyšsko -
lotyština -
Zāļu valsts aģentūra
fluditec 50 mg/ml sīrups
laboratoire innotech international sas, france - karbocisteīns - sīrups - 50 mg/ml
Evropská unie -
lotyština -
EMA (European Medicines Agency)
delstrigo
merck sharp & dohme b.v. - doravirine, lamivudīnu, tenofovir disoproxil fumarate - hiv infekcijas - antivirals for treatment of hiv infections, combinations - delstrigo ir indicēts, lai ārstētu pieaugušos ar hiv inficēti 1 bez pagātnes vai tagadnes pierādījumus par pretestību nnrti klases, lamivudīnu, vai tenofovir. delstrigo is also indicated for the treatment of adolescents aged 12 years and older weighing at least 35 kg who are infected with hiv-1 without past or present evidence of resistance to the nnrti class, lamivudine, or tenofovir and who have experienced toxicities which preclude the use of other regimens that do not contain tenofovir disoproxil.
Evropská unie -
lotyština -
EMA (European Medicines Agency)
pifeltro
merck sharp & dohme b.v. - doravirine - hiv infekcijas - pretvīrusu līdzekļi sistēmiskai lietošanai - pifeltro is indicated, in combination with other antiretroviral medicinal products, for the treatment of adults, and adolescents aged 12 years and older weighing at least 35 kg infected with hiv 1 without past or present evidence of resistance to the nnrti class.
Evropská unie -
lotyština -
EMA (European Medicines Agency)
qdenga
takeda gmbh - dengue virus, serotype 2, expressing dengue virus, serotype 1, surface proteins, live, attenuated, dengue virus, serotype 2, expressing dengue virus, serotype 3, surface proteins, live, attenuated, dengue virus, serotype 2, expressing dengue virus, serotype 4, surface proteins, live, attenuated, dengue virus, serotype 2, live, attenuated - denges - vakcīnas - qdenga is indicated for the prevention of dengue disease in individuals from 4 years of age. the use of qdenga should be in accordance with official recommendations.
Evropská unie -
lotyština -
EMA (European Medicines Agency)
raptiva
serono europe limited - efalizumab - psoriāze - imūnsupresanti - Ārstēšana pieaugušiem pacientiem ar vidēji smagu hronisku plāksne psoriāze, kas nav spējušas reaģēt uz vai kuriem ir uz kontrindikāciju vai nepanes citu sistēmisku terapiju, ieskaitot ciklosporīni, metotreksātu un puva (skatīt 5. sadaļu. 1 - klīniskā efektivitāte).
